

CLAIMS

What is claimed:

1. A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof to the individual, in therapeutically effective amounts.
2. A method of Claim 1 wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.
3. A method of Claim 1 wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.
4. A method of Claim 1 wherein the tumor necrosis factor-mediated disease is selected from the group consisting of: autoimmune disease, acute or chronic immune disease, inflammatory disease and neurodegenerative disease.
5. A method of Claim 4 wherein the anti-tumor necrosis factor antibody is administered in multiple doses.
6. A method of Claim 5 wherein the anti-tumor necrosis factor antibody is a chimeric antibody.
7. A method of Claim 6 wherein the chimeric antibody binds to one or more amino acids of hTNF α selected from the group consisting of about 87-108 and about 59-80.

8. A method of Claim 6 wherein the chimeric antibody binds to the epitope of CA2.
9. A method of Claim 8 wherein the chimeric antibody is CA2.
10. A method for treating or preventing rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody to the individual, in therapeutically effective amounts.
11. A method of Claim 10 wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.
12. A method of Claim 10 wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.
13. A method of Claim 10 wherein the anti-tumor necrosis factor antibody is administered in multiple doses.
14. A method of Claim 13 wherein the anti-tumor necrosis factor antibody is a chimeric antibody.
15. A method of Claim 14 wherein the chimeric antibody binds to one or more amino acids of hTNF α selected from the group consisting of about 87-108 and about 59-80.
16. A method of Claim 14 wherein the chimeric antibody binds to the epitope of CA2.

17. A method of Claim 16 wherein the chimeric antibody is cA2.
18. A method for treating or preventing Crohn's disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor antibody to the individual, in therapeutically effective amounts.
19. A method of Claim 18 wherein the anti-tumor necrosis factor antibody and methotrexate are administered simultaneously.
20. A method of Claim 18 wherein the anti-tumor necrosis factor antibody and methotrexate are administered sequentially.
21. A method of Claim 18 wherein the anti-tumor necrosis factor antibody is administered in multiple doses.
22. A method of Claim 21 wherein the anti-tumor necrosis factor antibody is a chimeric antibody.
23. A method of Claim 22 wherein the chimeric antibody binds to one or more amino acids of hTNF α selected from the group consisting of about 87-108 and about 59-80.
24. A method of Claim 22 wherein the chimeric antibody binds to the epitope of cA2.
25. A method of Claim 22 wherein the chimeric antibody is cA2.

- ADD
AZ